| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.075 | 0.2 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.081 | 0.2 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.069 | 0.2 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.2 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | 0.052 | 0.2 |